What are the treatment options for non–small cell lung cancer (NSCLC) in patients with ROS-1 mutations?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with ROS-1 mutations, the following agents are used:

  • Crizotinib (Xalkori)
  • Entrectinib (Rozlytrek)
  • Ceritinib (Zykadia)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!